Suppr超能文献

壳聚糖用于体重减轻的单盲、安慰剂对照随机临床研究。

Single-blind, placebo controlled randomised clinical study of chitosan for body weight reduction.

作者信息

Trivedi V R, Satia M C, Deschamps A, Maquet V, Shah R B, Zinzuwadia P H, Trivedi J V

机构信息

Ethicare Clinical Trial Services, Titanium City Centre, 100 Feet Road, Ahmedabad, 380015, Ahmedabad, India.

KITOZYME, Parc Industriel des Hauts-Sart, Zone 2, Rue de Milmort 680, 4040, Herstal, Belgium.

出版信息

Nutr J. 2016 Jan 8;15:3. doi: 10.1186/s12937-016-0122-8.

Abstract

BACKGROUND

Chitosan is a dietary fibre which acts by reducing fat absorption and thus used as a means for controlling weight. Weight loss clinical trial outcomes, however, have contradictory results regarding its efficacy. The primary objective of the present study was to evaluate the efficacy and safety of a chitosan from fungal origin in treatment of excess weight in the absence of dietary restrictions.

METHODS

A phase IV, randomised, multicentre, single-blind, placebo-controlled, clinical study was conducted by administering chitosan capsules (500 mg, five/day) and indistinguishable placebo capsules as daily supplements to 96 overweight and obese subjects for 90 days. The study participants were divided in 2:1 ratio to receive either chitosan (n = 64) or placebo (n = 32). Efficacy was assessed by measuring body weight, body composition parameters, anthropometric measurements, HbA1C level and lipid profile at day 45 and day 90. Also, short form-36 quality of life (QoL) questionnaire was assessed to evaluate improvement in life-style and dietary habits were recorded for calorie intake. Safety was assessed by evaluating safety parameters and monitoring adverse events.

RESULTS

The mean changes in body weight were -1.78 ± 1.37 kg and -3.10 ± 1.95 kg at day 45 and day 90 respectively in chitosan group which were significantly different (p < 0.0001) as compared to placebo. BMI was decreased by10.91 fold compared to placebo after 90 day administration. In concert with this, there was also reduction in body composition and anthropometric parameters together with improvement in QoL score. Chitosan was also able to reduce HbA1C levels (below 6 %) in subjects who had initial higher values. The mean caloric intake shows that there was no change in dietary habits of subjects in both groups. Lipid levels were unaffected and all adverse events were mild in nature and unrelated to study treatment.

CONCLUSION

Chitosan from fungal origin was able to reduce the mean body weight up to 3 kg during the 90 day study period. Together with this, there was also improvement in body composition, anthropometric parameters and HbA1C, reflecting overall benefits for the overweight individuals. Additionally, there was also improvement in QoL score. It was safe and well tolerated by all subjects.

TRIAL REGISTRATION

CTRI/2014/08/004901.

摘要

背景

壳聚糖是一种膳食纤维,其作用机制是减少脂肪吸收,因此被用作控制体重的一种手段。然而,关于其疗效,减肥临床试验结果相互矛盾。本研究的主要目的是评估一种真菌来源的壳聚糖在无饮食限制情况下治疗超重的疗效和安全性。

方法

进行了一项IV期、随机、多中心、单盲、安慰剂对照的临床研究,将壳聚糖胶囊(500毫克,每日5粒)和难以区分的安慰剂胶囊作为每日补充剂给予96名超重和肥胖受试者,为期90天。研究参与者按2:1的比例分为两组,分别接受壳聚糖(n = 64)或安慰剂(n = 32)。在第45天和第90天通过测量体重、身体成分参数、人体测量指标、糖化血红蛋白水平和血脂谱来评估疗效。此外,还评估了36项简短生活质量(QoL)问卷,以评估生活方式的改善情况,并记录饮食习惯和卡路里摄入量。通过评估安全参数和监测不良事件来评估安全性。

结果

壳聚糖组在第45天和第90天的体重平均变化分别为-1.78±1.37千克和-3.10±1.95千克,与安慰剂组相比有显著差异(p < 0.0001)。给药90天后,与安慰剂相比,体重指数降低了10.91倍。与此同时,身体成分和人体测量参数也有所降低,生活质量评分有所提高。壳聚糖还能够降低初始值较高的受试者的糖化血红蛋白水平(低于6%)。平均卡路里摄入量表明两组受试者的饮食习惯没有变化。血脂水平未受影响,所有不良事件性质轻微,与研究治疗无关。

结论

在为期90天的研究期间,真菌来源的壳聚糖能够使平均体重减轻多达3千克。与此同时,身体成分、人体测量参数和糖化血红蛋白也有所改善,这反映了对超重个体的总体益处。此外,生活质量评分也有所提高。它对所有受试者来说都是安全且耐受性良好的。

试验注册

CTRI/2014/08/004901。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1db3/4706713/9afdef4f0942/12937_2016_122_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验